绥美凯是阻断药吗？

(Alias: Doptabalamid Tablets) is used to treat adults and adolescents over 12 years old (weight at least 40kg) infected with human immunodeficiency virus (HIV). Is Suimeikan a blocking drug?

Suimeikai is a blocking drug, which is an imported specialized blocking drug.

Suimeikai is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China. It is the only three-in-one compound drug with dolutegravir (DTG) as the core. It has the characteristics of high efficiency, good tolerance, high resistance barrier, and few drug interactions. It can be taken once a day, one tablet at a time, which can significantly reduce the medication burden of HIV-infected patients, thereby improving patients' medication compliance.

Suimei Kai drug overdose:

After an acute overdose of dolutegravir, abacavir, or lamivudine, no specific symptoms or signs other than those listed as adverse reactions have been noted.

There is no specific treatment for Suimeike overdose. If overdose occurs, the patient should receive supportive care and appropriate monitoring if necessary. Because lamivudine is dialyzable, continuous hemodialysis may be used in the treatment of overdose, but this has not been studied. It is unknown whether abacavir is eliminated by peritoneal dialysis or hemodialysis. Dolutegravir is highly bound to plasma proteins, so it is unlikely to be significantly removed using dialysis.

Drug interactions of Suimeikai (alias: Dotiabalamid Tablets):

Contains dolutegravir, abacavir, and lamivudine; therefore, interactions seen with these drugs when used alone are related to Trimax. No clinically significant drug interactions are expected between dolutegravir, abacavir, and lamivudine.

Recommended related hot articles: /newsDetail/71879.html